drugset
drugset / Trial / NCT05914610

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

NCT05914610 ↗

Phase 3 Not yet recruiting 100 enrolled Fujian Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Timeline

Start
2023-09-01
Primary completion
2025-07-30
Completion
2028-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Envolimab Unknown 300 mg Other
Subject Fruquintinib Small molecule 3 mg Oral
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background S-1 Small molecule 40 mg Oral
Background S-1 Small molecule 50 mg Oral
Background S-1 Small molecule 60 mg Oral

Indications

gastric cancer